EXACT SCIENCES CORP

Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests, offering solutions that aid patients and healthcare professionals in making timely decisions. The company's product portfolio focuses on earlier cancer detection and treatment guidance, specifically through screening and precision oncology tests. Key products include the Cologuard and Oncotype DX tests. In 2025, Exact Sciences delivered over 5.5 million results to patients with its cancer tests and grew revenue by 18%. The company generated $491.4 million in cash from operating activities for the year ended December 31, 2025, an improvement of $280.9 million compared to December 31, 2024. During 2025, Exact Sciences launched Cologuard Plus, its next-generation Cologuard test; Oncodetect, a molecular residual disease (MRD) test; and Cancerguard, a multi-cancer early detection (MCED) blood test. Medicare reimbursement for the Oncodetect test was obtained through the MolDX program, effective April 2025, for serial use in patients with stage II, III, and resectable stage IV colorectal cancer in adjuvant and recurrence monitoring settings over a five-year period. The company also entered into an exclusive license agreement with Freenome Holdings, Inc. for blood-based colorectal cancer screening. On November 19, 2025, Exact Sciences entered into a Merger Agreement with Abbott Laboratories and Badger Merger Sub I, Inc.